MetaVia Inc. strengthens its leadership team with the appointment of Sarah Browne as Chief Medical Officer to accelerate the development of its metabolic disease portfolio, including the ongoing advancement of pemvidutide.
MetaVia announced the appointment of Sarah Browne as Chief Medical Officer, a routine leadership change with no direct financial impact.
MetaVia Inc. has named Sarah Browne as its new Chief Medical Officer to oversee the company's metabolic and liver disease drug development programs. Browne brings extensive experience in advancing therapies through Phase 2 and Phase 3 trials, specifically within the GLP-1/glucagon receptor agonist space.
As Chief Medical Officer, Sarah Browne will lead the company's drug development programs, with a specific emphasis on metabolic and liver diseases such as MASH.